Hutchmed
As of the edition of 20 October 2026, Hutchmed runs 17 drugs, 2 of them marketed; it is on route A at 3 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 8 |
| Went quiet | 1 |
| Stopped | 4 |
| Status not established | 2 |
| Total | 17 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Tislelizumab | Ends 2036 (computed from the first US licence) | 2 |
| Fruquintinib | Ends 2035 (patent) | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 3 targets, route B at 0 targets.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Hutchmed needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 60 trials led
- Blood and lymph: 18 trials led
- Digestive system: 17 trials led